

# Chin B Eap

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2681224/chin-b-eap-publications-by-citations.pdf>  
**Version:** 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

240 papers	9,079 citations	54 h-index	83 g-index
250 ext. papers	10,070 ext. citations	3.9 avg, IF	5.65 L-index

#	Paper	IF	Citations
240	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. <i>Lancet, The</i> , <b>2002</b> , 359, 30-6	4.0	575
239	Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. <i>Clinical Pharmacokinetics</i> , <b>2002</b> , 41, 1153-93	6.2	406
238	Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. <i>American Journal of Psychiatry</i> , <b>1998</b> , 155, 499-504	11.9	233
237	Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 81, 719-28	6.1	204
236	ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 668-81	6.1	194
235	Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 78, 593-604	6.1	184
234	Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 97-112	3.8	138
233	Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. <i>British Journal of Pharmacology</i> , <b>2010</b> , 160, 919-30	8.6	131
232	The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. <i>British Journal of Pharmacology</i> , <b>2010</b> , 160, 907-18	8.6	123
231	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 300-9	1.9	122
230	Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 225-41	6.2	118
229	Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. <i>Clinical Pharmacology and Therapeutics</i> , <b>1990</b> , 47, 338-46	6.1	113
228	CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 474-82	3.2	105
227	ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. <i>Journal of Clinical Psychopharmacology</i> , <b>2009</b> , 29, 319-26	1.7	98
226	Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. <i>Journal of Chromatographic Science</i> , <b>1998</b> , 36, 365-71	1.4	96
225	Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 85, 485-94	6.1	94
224	The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. <i>Pharmacogenetics and Genomics</i> , <b>1999</b> , 9, 55-60		94

223	The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 877-83	1.9	93
222	Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. <i>Drug and Alcohol Dependence</i> , <b>2000</b> , 61, 47-54	4.9	90
221	Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2009</b> , 50, 1000-8	3.5	88
220	Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. <i>International Clinical Psychopharmacology</i> , <b>2002</b> , 17, 141-3	2.2	88
219	Cytochrome P450 2D6 genotype and methadone steady-state concentrations. <i>Journal of Clinical Psychopharmacology</i> , <b>2001</b> , 21, 229-34	1.7	86
218	Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. <i>Pharmacogenetics and Genomics</i> , <b>2003</b> , 13, 39-47		84
217	N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, 317-327	1.3	83
216	Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 214-9	1.7	83
215	Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 307-15	1.9	79
214	F44. AN ADD-ON TRIAL WITH N-ACETYL-CYSTEINE (NAC) IN EARLY PSYCHOSIS PATIENTS: TOWARDS BIOMARKER GUIDED TREATMENT. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, S236-S236	1.3	78
213	Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. <i>Psychopharmacology</i> , <b>2005</b> , 181, 751-60	4.7	78
212	Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. <i>International Journal of Neuropsychopharmacology</i> , <b>2005</b> , 8, 403-10	5.8	78
211	F227. PSYCHOLOGICAL TRAUMA OCCURRING DURING ADOLESCENCE IS ASSOCIATED WITH AN INCREASED RISK OF GREATER WAIST CIRCUMFERENCE IN EARLY PSYCHOSIS PATIENTS INDEPENDENTLY OF MEDICATION. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, S310-S310	1.3	78
210	Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. <i>Pharmacological Research</i> , <b>2008</b> , 58, 344-7	10.2	77
209	Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. <i>Archives of Internal Medicine</i> , <b>2010</b> , 170, 529-36		75
208	Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. <i>European Journal of Clinical Pharmacology</i> , <b>2004</b> , 60, 237-46	2.8	74
207	Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 539-43	3.2	74
206	Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , <b>1996</b> , 50, 385-9	2.8	74

205	Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 117-25	6.1	70
204	Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2008</b> , 32, 1722-7	5.5	70
203	Probable metabolic interaction between methadone and fluvoxamine in addict patients. <i>Therapeutic Drug Monitoring</i> , <b>1994</b> , 16, 42-5	3.2	70
202	Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. <i>European Journal of Clinical Pharmacology</i> , <b>2004</b> , 60, 231-6	2.8	69
201	Methadone maintenance treatment and St. John's Wort - a case report. <i>Pharmacopsychiatry</i> , <b>2003</b> , 36, 35-7	2	68
200	Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , <b>1996</b> , 682, 265-72		67
199	Cytochrome P-450 activities in human and rat brain microsomes. <i>Brain Research</i> , <b>2000</b> , 855, 235-43	3.7	66
198	Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. <i>Drug Safety</i> , <b>2006</b> , 29, 735-68	5.1	64
197	Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 5472-5482	5.6	64
196	Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram. <i>European Neuropsychopharmacology</i> , <b>2002</b> , 12, 433-44	1.2	63
195	Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. <i>Biomedical Applications</i> , <b>1996</b> , 686, 51-63		63
194	Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. <i>Journal of Chromatography A</i> , <b>2013</b> , 1292, 160-72	4.5	59
193	The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. <i>Pharmacopsychiatry</i> , <b>2002</b> , 35, 50-6	2	59
192	Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. <i>Journal of Clinical Psychopharmacology</i> , <b>2002</b> , 22, 211-5	1.7	59
191	Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. <i>Journal of Clinical Psychopharmacology</i> , <b>1997</b> , 17, 113-7	1.7	58
190	CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 689-99	3.2	57
189	Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 60, 865-73	2.8	56
188	Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 59, 322-31	6.1	56

187	Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 307-18	6.1	55
186	Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography. <i>Biomedical Applications</i> , <b>1998</b> , 719, 234-8		54
185	Brain dopamine response in human opioid addiction. <i>British Journal of Psychiatry</i> , <b>2008</b> , 193, 65-72	5.4	53
184	CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. <i>Hypertension</i> , <b>2007</b> , 49, 1007-14	8.5	53
183	Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 553-5	3.2	49
182	High interindividual variability of methadone enantiomer blood levels to dose ratios. <i>Archives of General Psychiatry</i> , <b>1998</b> , 55, 89-90		49
181	Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. <i>Journal of Clinical Psychopharmacology</i> , <b>2001</b> , 21, 330-4	1.7	48
180	In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. <i>Pharmacology</i> , <b>2007</b> , 80, 304-11	2.3	47
179	The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens. <i>Molecular Psychiatry</i> , <b>2015</b> , 20, 1448-59	15.1	45
178	Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension. <i>Human Molecular Genetics</i> , <b>2012</b> , 21, 3283-92	5.6	45
177	Inflammation-induced changes in expression and glycosylation of genetic variants of alpha 1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice. <i>Biochemical Journal</i> , <b>1991</b> , 276 ( Pt 2), 343-7	3.8	45
176	Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 209-14	3.2	44
175	Very high cytochrome P4501A2 activity and nonresponse to clozapine. <i>Archives of General Psychiatry</i> , <b>1998</b> , 55, 1048-50		44
174	Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. <i>Journal of Clinical Psychiatry</i> , <b>2015</b> , 76, e1417-23	4.6	43
173	Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 95, 254-7	6.1	42
172	Identification of a novel splice-site mutation in the CYP1A2 gene. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 56, 341-4	3.8	42
171	Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. <i>European Neuropsychopharmacology</i> , <b>2002</b> , 12, 255-60	1.2	41
170	Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 511-22	3.2	40

169	Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. <i>Journal of Clinical Psychopharmacology</i> , <b>2007</b> , 27, 273-8	1.7	40
168	Can valproic acid be an inducer of clozapine metabolism?. <i>Pharmacopsychiatry</i> , <b>2014</b> , 47, 89-96	2	39
167	Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 76, 55-63	6.1	39
166	Isoelectric focusing of alpha-1 acid glycoprotein (orosomucoid) in immobilized pH-gradients with 8M urea: detection of its desialylated variants using an alkaline phosphatase-linked secondary antibody system. <i>Electrophoresis</i> , <b>1988</b> , 9, 650-4	3.6	39
165	Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 413-27	4.1	38
164	Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 84-93	1.9	38
163	Efavirenz decreases methadone blood concentrations. <i>Aids</i> , <b>2000</b> , 14, 1291-2	3.5	38
162	Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 78, 135-44	3.8	37
161	Influence of CRT1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population. <i>JAMA Psychiatry</i> , <b>2013</b> , 70, 1011-9	14.5	37
160	Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2007</b> , 32, 641-9	2.2	37
159	Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionization-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2004</b> , 802, 339-45	3.2	37
158	Association of CYP3A5 genotypes with blood pressure and renal function in African families. <i>Journal of Hypertension</i> , <b>2006</b> , 24, 923-9	1.9	36
157	Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma. <i>Biomedical Applications</i> , <b>1995</b> , 669, 271-9		36
156	Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 1259-72	6.2	35
155	Blood pressure in relation to coffee and caffeine consumption. <i>Current Hypertension Reports</i> , <b>2014</b> , 16, 468	4.7	35
154	Use of transgenic mice for the characterization of human alpha 1-acid glycoprotein (orosomucoid) variants. <i>Human Genetics</i> , <b>1989</b> , 84, 89-91	6.3	35
153	Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2012</b> , 64-65, 16-25	3.5	34
152	Population pharmacokinetic study of memantine: effects of clinical and genetic factors. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 211-23	6.2	34



151	Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography-electrospray mass spectrometry for therapeutic drug monitoring. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2012</b> , 885-886, 117-30	3.2	34
150	Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 366-74	3.2	34
149	Determination of plasma levels of citalopram and its demethylated and deaminated metabolites by gas chromatography and gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , <b>1993</b> , 616, 221-8		34
148	Quantification of typical antipsychotics in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2014</b> , 88, 36-44	3.5	33
147	Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. <i>Pharmacopsychiatry</i> , <b>1996</b> , 29, 108-10	2	33
146	Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. <i>Drug and Alcohol Dependence</i> , <b>2003</b> , 69, 205-11	4.9	33
145	Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 896-907	4.6	32
144	Arrestin2 influences the response to methadone in opioid-dependent patients. <i>Pharmacogenomics Journal</i> , <b>2011</b> , 11, 258-66	3.5	31
143	Quantification of nicotine, cotinine, trans-3- $\alpha$ -hydroxycotinine and varenicline in human plasma by a sensitive and specific UPLC-tandem mass-spectrometry procedure for a clinical study on smoking cessation. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2011</b> , 879, 3574-82	3.2	31
142	Clinical outcome after trimipramine in patients with delusional depression - a pilot study. <i>Pharmacopsychiatry</i> , <b>2003</b> , 36, 12-7	2	30
141	Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. <i>Therapeutic Drug Monitoring</i> , <b>1996</b> , 18, 570-2	3.2	30
140	Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. <i>Journal of Psychiatric Research</i> , <b>2012</b> , 46, 540-8	5.2	29
139	Prevalence of substance use in a Swiss psychiatric hospital: interview reports and urine screening. <i>Addictive Behaviors</i> , <b>2006</b> , 31, 1252-8	4.2	28
138	Increased trimipramine plasma levels during fluvoxamine comedication. <i>European Neuropsychopharmacology</i> , <b>1994</b> , 4, 15-20	1.2	28
137	Variations in relative concentrations of variants of human alpha 1-acid glycoprotein after acute-phase conditions. <i>Clinica Chimica Acta</i> , <b>1991</b> , 203, 379-85	6.2	28
136	Associations of ambulatory blood pressure with urinary caffeine and caffeine metabolite excretions. <i>Hypertension</i> , <b>2015</b> , 65, 691-6	8.5	27
135	Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram. <i>Therapeutic Drug Monitoring</i> , <b>2003</b> , 25, 600-8	3.2	27
134	Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 283-90	1.7	27

133	CYP3A activity measured by the midazolam test is not related to 3435 C>T polymorphism in the multiple drug resistance transporter gene. <i>Pharmacogenetics and Genomics</i> , <b>2004</b> , 14, 255-60		27
132	Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction. <i>Journal of Chromatography A</i> , <b>2015</b> , 1420, 119-28	4.5	26
131	Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking. <i>Pharmacogenetics and Genomics</i> , <b>2012</b> , 22, 143-51	1.9	26
130	CYP3A5 and ABCB1 genes and hypertension. <i>Pharmacogenomics</i> , <b>2009</b> , 10, 477-87	2.6	26
129	Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1998</b> , 64, 52-7	6.1	26
128	Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours. <i>British Journal of Clinical Pharmacology</i> , <b>2013</b> , 75, 1007-18	3.8	25
127	Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 270-5	3.2	25
126	Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 171-82	1.6	25
125	Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. <i>Pharmacopsychiatry</i> , <b>2000</b> , 33, 112-5	2	25
124	Orosomucoid (alpha-1 acid glycoprotein) phenotyping by use of immobilized pH gradients with 8 M urea and immunoblotting. A new variant encountered in a population study. <i>Human Genetics</i> , <b>1988</b> , 80, 183-5	6.3	25
123	No influence of ABCB1 haplotypes on methadone dosage requirement. <i>Clinical Pharmacology and Therapeutics</i> , <b>2008</b> , 83, 668-9; author reply 669-70	6.1	24
122	Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. <i>Journal of Psychopharmacology</i> , <b>2004</b> , 18, 559-566	4.6	23
121	Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. <i>Clinical Pharmacokinetics</i> , <b>2016</b> , 55, 1521-1533	6.2	22
120	Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 166-70	3.2	22
119	The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2010</b> , 6, 953-65	5.5	21
118	Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. <i>Journal of Clinical Psychopharmacology</i> , <b>2012</b> , 32, 622-9	1.7	21
117	Determination of the Enantiomers of Mianserin and its Metabolites in Plasma by Capillary Electrophoresis After Liquid-Liquid Extraction and On-Column Sample Preconcentration. <i>Journal of Chromatographic Science</i> , <b>1997</b> , 35, 315-320	1.4	21
116	Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 152-5	3.2	21



115	Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1988</b> , 337, 220-4	3.4	21
114	Steady state concentrations of the enantiomers of mianserin and desmethylnianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 7-13	3.2	21
113	Binding of amitriptyline to alpha 1-acid glycoprotein and its variants. <i>Journal of Pharmacy and Pharmacology</i> , <b>1988</b> , 40, 767-70	4.8	20
112	Automated LC-MS method for the fast stereoselective determination of methadone in plasma. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2003</b> , 41, 1615-21	5.9	20
111	Enantiomeric antidepressant drugs should be considered on individual merit. <i>Human Psychopharmacology</i> , <b>2001</b> , 16, S85-S92	2.3	20
110	Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 228-31	3.2	20
109	Plasma levels of trimipramine and metabolites in four patients: determination of the enantiomer concentrations of the hydroxy metabolites. <i>Therapeutic Drug Monitoring</i> , <b>1992</b> , 14, 380-5	3.2	20
108	Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 289-98	1.7	19
107	Quantification of 4 antidepressants and a metabolite by LC-MS for therapeutic drug monitoring. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2011</b> , 879, 1544-50	3.3	19
106	Determination of the enantiomers of mianserin, desmethylnianserin, and 8-hydroxymianserin in the plasma and urine of mianserin-treated patients. <i>Chirality</i> , <b>1994</b> , 6, 555-63	2.1	19
105	Artifacts in the analysis of thioridazine and other neuroleptics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>1993</b> , 11, 451-7	3.5	19
104	Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high performance liquid chromatography tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2013</b> , 77, 1-8	3.5	18
103	Determination and distribution of clotiapine (Entumine) in human plasma, post-mortem blood and tissue samples from clotiapine-treated patients and from autopsy cases. <i>Forensic Science International</i> , <b>2007</b> , 170, 193-9	2.6	18
102	Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2005</b> , 29, 952-6	5.5	18
101	Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 286-92	1.9	17
100	Simultaneous determination of antideementia drugs in human plasma for therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 227-38	3.2	17
99	Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R,S)-methadone in clinical samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2009</b> , 877, 2301-7	3.2	17
98	Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. <i>International Journal of Neuropsychopharmacology</i> , <b>2000</b> , 3, 55-60	5.8	17

97	Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping. <i>Pharmacopsychiatry</i> , <b>1998</b> , 31, 72	2	17
96	Light-Induced Racemization. <i>Therapeutic Drug Monitoring</i> , <b>1991</b> , 13, 356-362	3.2	17
95	Risperidone-induced symptomatic hyperprolactinaemia in adolescents. <i>Journal of Clinical Psychopharmacology</i> , <b>2006</b> , 26, 167-71	1.7	16
94	Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence - an update. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 949-963	4.1	15
93	Oral and intravenous methadone use: some clinical and pharmacokinetic aspects. <i>Drug and Alcohol Dependence</i> , <b>1999</b> , 55, 137-43	4.9	15
92	Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression. <i>Journal of Affective Disorders</i> , <b>2016</b> , 198, 43-9	6.6	15
91	Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 1113-20	2.8	14
90	Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects. <i>Neuropsychobiology</i> , <b>1992</b> , 25, 214-20	4	14
89	Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 219-229	4.9	14
88	Association between 28 single nucleotide polymorphisms and type 2 diabetes mellitus in the Kazakh population: a case-control study. <i>BMC Medical Genetics</i> , <b>2017</b> , 18, 76	2.1	13
87	Variability of response to methadone: genome-wide DNA methylation analysis in two independent cohorts. <i>Epigenomics</i> , <b>2016</b> , 8, 181-95	4.4	13
86	Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity. <i>Pharmacopsychiatry</i> , <b>2006</b> , 39, 150-2	2	13
85	High dose of depot risperidone in a nonresponder schizophrenic patient. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 673-4	1.7	13
84	Two-step chromatographic purification of human plasma alpha(1)-acid glycoprotein: its application to the purification of rare phenotype samples of the protein and their study by chromatography on immobilized metal chelate affinity adsorbent. <i>Biomedical Applications</i> , <b>1996</b> , 678, 1-14		13
83	Stereoselective determination of citalopram and desmethylocitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2016</b> , 131, 233-245	3.5	12
82	Adherence to antidepressant treatment: what the doctor thinks and what the patient says. <i>Pharmacopsychiatry</i> , <b>2012</b> , 45, 204-7	2	12
81	Association of ABCB1 genetic variants with renal function in Africans and in Caucasians. <i>BMC Medical Genomics</i> , <b>2008</b> , 1, 21	3.7	12
80	Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. <i>Addiction Biology</i> , <b>2003</b> , 8, 59-66	4.6	12

79	Relation of 24-hour urinary caffeine and caffeine metabolite excretions with self-reported consumption of coffee and other caffeinated beverages in the general population. <i>Nutrition and Metabolism</i> , <b>2016</b> , 13, 81	4.6	12
78	Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-electrospray mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2017</b> , 1057, 101-109	3.2	11
77	Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2018</b> , 28, 258-265	2.9	11
76	Death following acute poisoning by moclobemide. <i>Forensic Science International</i> , <b>2004</b> , 140, 101-7	2.6	11
75	Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139155	3.7	11
74	Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs. <i>Dialogues in Clinical Neuroscience</i> , <b>2016</b> , 18, 313-322	5.7	11
73	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.. <i>Pharmacopsychiatry</i> , <b>2021</b> , 55,	2	11
72	Associations of Urinary Caffeine and Caffeine Metabolites With Arterial Stiffness in a Large Population-Based Study. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 586-596	6.4	10
71	Gender-specific alteration of energy balance and circadian locomotor activity in the Crtc1 knockout mouse model of depression. <i>Translational Psychiatry</i> , <b>2017</b> , 7, 1269	8.6	10
70	Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression?. <i>Critical Care</i> , <b>2007</b> , 11, 119	10.8	10
69	Time course of response to paroxetine: influence of plasma level. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2007</b> , 31, 892-900	5.5	10
68	Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. <i>CNS Drugs</i> , <b>2019</b> , 33, 1201-1222	6.7	10
67	Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. <i>Pharmacogenetics and Genomics</i> , <b>2015</b> , 25, 246-58	1.9	9
66	Determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma by gas chromatography--mass spectrometry. <i>Biomedical Applications</i> , <b>1998</b> , 705, 139-44		9
65	Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status. <i>Journal of Clinical Psychopharmacology</i> , <b>2006</b> , 26, 679-81	1.7	9
64	Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone. <i>Journal of Clinical Psychopharmacology</i> , <b>2016</b> , 36, 90-2	1.7	9
63	CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. <i>Pharmacogenomics Journal</i> , <b>2017</b> , 17, 69-75	3.5	8
62	On the usefulness of therapeutic drug monitoring of methadone. <i>European Addiction Research</i> , <b>2000</b> , 6, 31-3	4.6	8

61	Serotonin toxicity after addition of mirtazapine to escitalopram. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 540-1	1.7	7
60	Aripiprazole and suicidality. <i>International Clinical Psychopharmacology</i> , <b>2006</b> , 21, 125-6	2.2	7
59	Increase of oral methadone dose in methadone injecting patients: a pilot study. <i>Journal of Addictive Diseases</i> , <b>2003</b> , 22, 7-17	1.7	7
58	Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 547-557	1.9	7
57	Severe manic episode associated with tramadol in a patient with recurrent depressive disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 203-4	1.7	6
56	Very long half-life of paroxetine following intoxication in an extensive cytochrome P4502D6 metabolizer. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 567-9	3.2	6
55	Comment: opiate withdrawal symptoms induced by antiretroviral drugs. <i>Annals of Pharmacotherapy</i> , <b>2000</b> , 34, 1077-8	2.9	6
54	Determination of trimipramine and its demethylated and hydroxylated metabolites in plasma by gas chromatography-mass spectrometry. <i>Biomedical Applications</i> , <b>1994</b> , 652, 97-103		6
53	Weighted Genetic Risk Scores and Prediction of Weight Gain in Solid Organ Transplant Populations. <i>PLoS ONE</i> , <b>2016</b> , 11, e0164443	3.7	6
52	Genetic and clinic predictors of new onset diabetes mellitus after transplantation. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 53-64	3.5	6
51	A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants. <i>Drug Development Research</i> , <b>2020</b> , 81, 102-113	5.1	6
50	Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. <i>Psychiatric Quarterly</i> , <b>2013</b> , 84, 329-35	4.1	5
49	Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 544-52	1.7	5
48	Lack of association between genetic polymorphisms of ARRB2 and alcohol dependence in a Caucasian population. <i>Alcohol and Alcoholism</i> , <b>2010</b> , 45, 590-1	3.5	5
47	Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz. <i>American Journal of Drug and Alcohol Abuse</i> , <b>2011</b> , 37, 264-8	3.7	5
46	Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. <i>Journal of Psychopharmacology</i> , <b>2004</b> , 18, 559-66	4.6	5
45	Caffeine Consumption in Switzerland: Results from the First National Nutrition Survey MenuCH. <i>Nutrients</i> , <b>2019</b> , 12,	6.7	5
44	Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 1486-1497 <sup>8</sup>		5

43	Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 238-246	8.7	4
42	Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs. <i>Pharmacogenetics and Genomics</i> , <b>2017</b> , 27, 464-472	1.9	4
41	High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2004</b> , 8, 191-5	2.4	4
40	Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatment. <i>Chirality</i> , <b>2002</b> , 14, 347-50	2.1	4
39	Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy. <i>Experimental and Clinical Psychopharmacology</i> , <b>2017</b> , 25, 353-362	3.2	4
38	Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 371-382	6.2	4
37	Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs. <i>Gene</i> , <b>2017</b> , 628, 8-15	3.8	3
36	Prevalence of methadone injection in three Swiss cities. <i>Presse Medicale</i> , <b>2005</b> , 34, 776-80	2.2	3
35	Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in Early Psychosis patients treated with psychotropic medication. <i>PLoS ONE</i> , <b>2020</b> , 15, e0242569	3.7	3
34	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. <i>World Journal of Biological Psychiatry</i> , <b>2021</b> , 22, 561-628	3.8	3
33	Prevalence of ECG abnormalities and risk factors for QTc interval prolongation in hospitalized psychiatric patients. <i>Therapeutic Advances in Psychopharmacology</i> , <b>2019</b> , 9, 2045125319891386	4.9	3
32	Psychotropic Drug Prescription in Adolescents: A Retrospective Study in a Swiss Psychiatric University Hospital. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2018</b> , 28, 192-204	2.9	3
31	Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 573	5	3
30	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2022-2032	3.8	2
29	Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. <i>European Journal of Clinical Pharmacology</i> , <b>2019</b> , 75, 939-949	2.8	2
28	The effect of a single dose of escitalopram on sensorimotor networks. <i>Brain and Behavior</i> , <b>2018</b> , 8, e009754	3.5	2
27	Pharmacogenetics of chiral psychotropic drugs <b>2002</b> , 181-214		2
26	Evaluation of Cardiometabolic Risk in a Large Psychiatric Cohort and Comparison With a Population-Based Sample in Switzerland. <i>Journal of Clinical Psychiatry</i> , <b>2020</b> , 81,	4.6	2



25	The role of cytochrome P450 enzyme genetic variants in cannabis hyperemesis syndrome-A case report. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2021</b> , 129, 82-85	3.1	2
24	Association of genetic risk scores with body mass index in Swiss psychiatric cohorts. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 208-17	1.9	2
23	Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients. <i>Clinical Epigenetics</i> , <b>2019</b> , 11, 198	7.7	2
22	A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 1642-1653	3.8	1
21	Plasma levels and cerebrospinal fluid penetration of venlafaxine in a patient with a nonfatal overdose during a suicide attempt. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 398-9	1.7	1
20	Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 738	5.6	1
19	Substance Use in Adolescent Psychiatric Outpatients: Self-Report, Health Care Providers' Clinical Impressions, and Urine Screening. <i>Journal of Child and Adolescent Substance Abuse</i> , <b>2014</b> , 23, 1-8	0.6	1
18	Efficacy and tolerability of quetiapine in cluster B personality disorder: an open-label study. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2007</b> , 11, 123-8	2.4	1
17	Determination of human plasma levels of levo-alpha-acetylmethadol and its metabolites by gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2004</b> , 805, 141-6	3.2	1
16	Monitoring caffeine intake in children with a questionnaire and urine collection: a cross-sectional study in a convenience sample in Switzerland. <i>European Journal of Nutrition</i> , <b>2020</b> , 59, 3537-3543	5.2	1
15	Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations. <i>Journal of Nervous and Mental Disease</i> , <b>2001</b> , 189, 798-9	1.8	1
14	The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2020</b> , 126, 444-447	3.1	1
13	Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric population. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2021</b> , 129, 26-35	3.1	1
12	Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 360	8.6	1
11	Metabolomic alteration induced by psychotropic drugs: Short-term metabolite profile as a predictor of weight gain evolution. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 2544-2555	4.9	1
10	Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric Cohort.. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 756403	5	1
9	Bioavailability of Vortioxetine After a Roux-en-Y Gastric Bypass. <i>Obesity Surgery</i> , <b>2021</b> , 31, 1353-1356	3.7	0
8	Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study. <i>Pharmacopsychiatry</i> , <b>2021</b> , 54, 279-286	2	0



- |   |  |     |   |
|---|--|-----|---|
| 7 | Investigating the Relations Between Caffeine-Derived Metabolites and Plasma Lipids in 2 Population-Based Studies. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 3071-3085   | 6.4 | o |
| 6 | Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort.. <i>BMC Psychiatry</i> , <b>2022</b> , 22, 342 | 4.2 | o |
| 5 | La pharmacogénétique/pharmacogénomique en psychiatrie, perspectives théoriques et perspectives pour l'avenir. <i>Information Psychiatrique</i> , <b>2011</b> , 87, 697   |     |   |
| 4 | Multiple and simultaneous phenotyping tests: beware of ascorbic acid when determining the mephenytoin (S)/(R) ratio. <i>Clinica Chimica Acta</i> , <b>1998</b> , 271, 105-7  | 6.2 |   |
| 3 | Pharmakokinetik und therapeutisches Monitoring von Antidepressiva <b>2002</b> , 37-50  |     |   |
| 2 | Klinische Relevanz pharmakogenetischer Phänotypisierungen <b>1993</b> , 658-663  |     |   |
| 1 | Population biomonitoring of micronutrient intakes in children using urinary spot samples. <i>European Journal of Nutrition</i> , <b>2020</b> , 59, 3059-3068   | 5.2 |   |